Clinical implications of p53 mutations

Cellular and Molecular Life Sciences

Volumn 55, Issue 1, 1999, Pages 64-75

  Wallace Brodeur, R R ^a   Lowe, S W ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

Apoptosis; Cancer genetics; Chemotherapy; Clinical outcome; Prognosis; Tumor suppressor

Indexed keywords

CYTOTOXIC AGENT; PROTEIN P53;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESEARCH; CANCER THERAPY; CELL CYCLE G1 PHASE; DNA DAMAGE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DRUG RESISTANCE; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; PROTEIN BINDING;

EID: 0033054908     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050270     Document Type: Review

References (140)

1. 1 Cho Y., Gorina S., Jeffrey P. D. and Pavletich N. P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355
2. 2 Hall P. A. and Lane D. P. (1997) Tumor suppressors: a developing role for p53? Curr. Biol. 7: R144-147
3. 3 Bellamy C. O. (1997) p53 and apoptosis. Br. Med. Bull. 53: 522-538
4. 4 Dameron K. M., Volpert O. V., Tainsky M. A. and Bouck N. (1994) The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 59: 483-489
5. 5 El-Deiry W. (1998) p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227: 121-137
6. 6 Levine A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
7. 7 Moll U. M. and Schramm L. M. (1998) p53 an acrobat in tumorigenesis. Crit. Rev. Oral. Biol. Med. 9: 23-37
8. 8 O'Connor P. M. (1997) Mammalian G1 and G2 phase checkpoints. Cancer Surv. 29: 151-182
9. 9 Wynford T. D. (1996) p53: guardian of cellular senescence. J. Pathol. 180: 118-121
10. 10 Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T. et al. (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711
11. 11 Lowe S. W., Jacks T., Housman D. E. and Ruley H. E. (1994) Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA 91: 2026-2030
12. 12 Hermeking H. and Eick D. (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265: 2091-2093
13. 13 Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W. et al. (1996) Hypoxia-mediated selection of cells with diminished apoptolic potential in solid tumours. Nature 379: 88-91
14. 14 Rodriguez M. A., Ford R. J., Goodacre A., Selvanayagam P., Cabanillas F. and Deisseroth A. B. (1991) Chromosome 17p and p53 changes in lymphoma. Br. J. Haematol. 79: 575-582
15. 15 Nakai H., Misawa S., Taniwaki M., Horiike S., Takashima T., Seriu T. et al. (1994) Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. Br. J. Haematol. 87: 425-427
16. 16 Hsiao M. H., Yu A. L., Yeargin J., Ku D. and Haas M. (1994) Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 83: 2922-2930
17. 17 El Rouby S., Thomas A., Costin D., Rosenberg C. R., Potmesil M., Silber R. et al. (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDRI/MDR3 gene expression. Blood 82: 3452-3459
18. 18 Thompson A. M., Anderson T. J., Condie A., Prosser J., Chetty U., Carter D. C. et al. (1992) p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int. J. Cancer 50: 528-532
19. 19 Thorlacius S., Borresen A. L. and Eyfjord J. E. (1993) Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res. 53: 1637-1641
20. 20 Andersen T. I., Holm R., Nesland J. M., Heimdal K. R., Ottestad L. and Borresen A. L. (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer 68: 540-548
21. 21 Kovach J. S., Hartmann A., Blaszyk H., Cunningham J., Schaid D. and Sommer S. S. (1996) Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA 93: 1093-1096
22. 22 Bergh J., Norberg T., Sjogren S., Lindgren A. and Holmberg L. (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1: 1029-1034
23. 23 Aas T., Borresen A. L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J. E. et al. (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2: 811-814
24. 24 Formenti S. C., Dunnington G., Uzieli B., Lenz H., Keren-Rosenberg S., Silberman H. et al. (1997) Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int. J. Radial. Oncol. Biol. Phys. 39: 1059-1068
25. 25 Honda K., Sbisa E., Tullo A., Papeo P. A., Saccone C., Poole S. et al. (1998) p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br. J. Cancer 77: 776-782
26. 26 Pricolo V. E., Finkelstein S. D., Hansen K., Cole B. F. and Bland K. I. (1997) Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch. Surg. 132: 371-374; discussion 374-375
27. 27 Backe J., Gassel A. M., Hauber K., Krebs S., Bartek J., Caffier H. et al. (1997) p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int. J. Gynecol. Pathol. 16: 361-368
28. 28 Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R. and Shirakusa T. (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85: 2018-2023
29. 29 Huang C. L., Taki T., Adachi M., Konishi T., Higashiyama M., Kinoshita M. et al. (1998) Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int. J. Oncol. 12: 553-563
30. 30 Cordon-Cardo C., Latres E., Drobnjak M., Oliva M. R., Pollack D., Woodruff J. M. et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794-799
31. 31 Bardeesy N., Falkoff D., Petruzzi M. J., Nowak N., Zabel B., Adam M. et al. (1994) Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet. 7:91-97
32. 32 Esrig D., Elmajian D., Groshen S., Freeman J. A., Stein J. P., Chen S. C. et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331: 1259-1264
33. 33 Koch W. M., Brennan J. A., Zahurak M., Goodman S. N., Westra W. H., Schwab D. et al. (1996) p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88: 1580-1586
34. 34 Pollack I. F., Hamilton R. L., Finkelstein S. D., Campbell J. W., Martinez A. J., Sherwin R. N. et al. (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 57: 304-309
35. 35 Falette N., Paperin M. P., Treilleux I., Gratadour A. C., Peloux N., Mignotte H. et al. (1998) Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 58: 1451-1455
36. 36 Bardeesy N., Beckwith J. B., and Pelletier J. (1995) Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res. 55: 215-219
37. 37 Moll U. M., Ostermeyer A. G., Ahomadegbe J. C., Mathieu M. C. and Riou G (1995) p53 mediated tumour cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum. Pathol. 26: 1293-1301
38. 38 Fontanini G., Vignati S., Lucchi M., Mussi A., Calcinai A., Boldrini L. et al. (1997) Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br. J. Cancer 75: 1295-1301
39. 39 Takahashi Y., Bucana C. D., Cleary K. R. and Ellis L. M. (1998) p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J. Cancer 79: 34-38
40. 40 Tada M., Iggo R. D., Ishii N., Shinohe Y., Sakuma S., Estreicher A. et al. (1996) Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int. J. Cancer 67: 447-450
41. 41 Linke S. P., Clarkin K. C., Di Leonardo A., Tsou A. and Wahl G. M. (1996) A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10: 934-947
42. 42 Lotem J., Peled-Kamar M., Groner Y. and Sachs L. (1996) Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds and cytokines. Proc. Natl. Acad. Sci. USA 93: 9166-9171
43. 43 Serrano M., Lin A. W., McCurrach M. E., Beach D. and Lowe S. W. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602
44. 44 Lowe S. W., Schmilt E. M., Smith S. W., Osborne B. A. and Jacks T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849
45. 45 Clarke A. R., Purdie C. A., Harrison D. J., Morris R. G., Bird C. C., Hooper M. L. et al. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
46. 46 Kastan M. B., Zhan Q., El Deiry W., Carrier F., Jacks T., Walsh W. V. et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71: 587-597
47. 47 Slichenmyer W. J., Nelson W. G., Slebos R. J. and Kastan M. B. (1993) Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53: 4164-4168
48. 48 Guillouf C., Rosselli F., Krishnaraju K., Moustacchi E., Hoffman B. and Liebermann D. A. (1995) p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 10: 2263-2270
49. 49 Di Leonardo A., Khan S. H., Linke S. P., Greco V., Seidita G. and Wahl G. M. (1997) DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57: 1013-1019
50. 50 Cross S. M., Sanchez C. A., Morgan C. A., Schimke M. K., Ramel S., Idzerda R. L. et al. (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356
51. 51 Minn A. J., Boise L. H. and Thompson C. B. (1996) Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10: 2621-2631
52. 52 Lanni J. S. and Jacks T. (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18: 1055-1064
53. 53 Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E. et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
54. 54 Merritt A. J., Potten C. S., Kemp C. J., Hickman J. A., Balmain A., Lane D. P. et al. (1994) The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 54: 614-617
55. 55 Sachs L. and Lotem J. (1993) Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82: 15-21
56. 56 Clarke A. R., Gledhill S., Hooper M. L., Bird C. C. and Wyllie A. H. (1994) p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9: 1767-1773
57. 57 Lowe S. W., Ruley H. E., Jacks T. and Housman D. E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
58. 58 Waldman T., Kinzler K. W. and Vogelstein B. (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55: 5187-5190
59. 59 Deng C., Zhang P., Harper J. W., Elledge S. J. and Leder P. (1995) Mice lacking p21CIP1/WAFI undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684
60. 60 Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T. and Hannon G. J. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557
61. 61 Brown J. P., Wei W., and Sedivy J. M. (1997) Bypass of senescence after disruption of p21CIP1/WAFI gene in normal diploid human fibroblasts. Science 277: 831-834
62. 62 Waldman T., Lengauer C., Kinzler K. W. and Vogelstein B. (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716
63. 63 Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B. et al. (1997) Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 3: 1034-1036
64. 64 Polyak K., Xia Y., Zweier J. L., Kinzler K. W. and Vogelstein B. (1997) A model for p53-induced apoptosis. Nature 389: 300-305
65. 65 Fan S., el-Deiry W. S., Bae I., Freeman J., Jondle D., Bhatia K. et al. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54: 5824-5830
66. 66 Iwadate Y., Tagawa M., Fujimoto S., Hirose M., Namba H., Sueyoshi K. et al. (1998) Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br. J. Cancer 77: 547-551
67. 67 Weinstein J. N., Myers T. G., O'Connor P. M., Friend S. H., Fornace A. J. Jr., Kohn K. W. et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349
68. 68 Xia F., Wang X., Wang Y. H., Tsang N. M., Yandell D. W., Kelsey K. T. et al. (1995) Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 55: 12-15
69. 69 Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I. et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157
70. 70 Wilson W. H., Teruya-Feldstein J., Fest T., Harris C., Steinberg S. M., Jaffe E. S. et al. (1997) Relationship of p53, bcl-2 and tumour proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89: 601-609
71. 71 Diccianni M. B., Yu J., Hsiao M., Mukherjee S., Shao L. E. and Yu A. L. (1994) Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84: 3105-3112
72. 72 Clahsen P. C., van de Velde C. J., Duval C., Pallud C., Mandard A. M., Delobelle D. A. et al. (1998) p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 16: 470-479
73. 73 Berns E. M., Klijn J. G., van Putten W. L., de Witte H. H., Look M. P., Meijer-van Gelder M. E. et al. (1998) p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J. Clin. Oncol. 16: 121-127
74. 74 Degeorges A., de Roquancourt A., Extra J. M., Espie M., Bourstyn E., de Cremoux P. et al. (1998) Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res. Treat. 47: 47-55
75. 75 Rozan S., Vincent-Salomon A., Zafrani B., Validire P., De Cremoux P., Bernoux A. et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer 79: 27-33
76. 76 Veronese S., Mauri F. A., Caffo O., Scaioli M., Aldovini D., Perrone G. et al. (1998) Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int. J. Cancer 79: 13-18
77. 77 Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E. et al. (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55: 4471-4478
78. 78 Kapranos N., Karaiosifidi H., Valavanis C., Kouri E. and Vasilaros S. (1997) Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res. 17: 2499-2505
79. 79 Bargou R. C., Daniel P. T., Mapara M. Y., Bommert K., Wagener C., Kallinich B. et al. (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 60: 854-859
80. 80 Sakakura C., Sweeney E. A., Shirahamu T., Igarashi Y., Hakomori S., Tsujimoto H. et al. (1997) Overexpression of bax enhances the radiation sensitivity in human breast cancer cells. Surg. Today 27: 90-93
81. 81 Sakakura C., Sweeney E. A., Shirahamu T., Igarashi Y., Hakomori S., Nakatani H. et al. (1996) Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer 67: 101-105
82. 82 Wagener C., Bargou R. C., Daniel P. T., Bommert K., Mapara M. Y., Royer H. D. et al. (1996) Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int. J. Cancer 67: 138-141
83. 83 Chresta C. M. and Hickman J. A. (1996) Oddball p53 in testicular tumors. Nature Med. 2: 745-746
84. 84 Chresta C. M., Masters J. R. and Hickman J. A. (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 56: 1834-1841
85. 85 Chin K. V., Ueda K., Pastan I. and Gottesman M. M. (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462
86. 86 Preudhomme C., Lepelley P., Vachee A., Soenen V., Quesnel B., Cosson A. et al. (1993) Relationship between p53 gene mutations and multidrug resistance (mdrl) gene expression in myelodysplastic syndromes. Leukemia 7: 1888-1890
87. 87 Schneider J., Rubio M. P., Barbazan M. J., Rodriguez-Escudero F. J., Seizinger B. R. and Castresana J. S. (1994) P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J. Natl. Cancer Inst. 86: 850-855
88. 88 Nabeya Y., Loganzo F. Jr., Maslak P., Lai L., de Oliveira A. R., Schwartz G. K. et al. (1995) The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer 64: 37-46
89. 89 O'Connor P. M., Jackman J., Jondle D., Bhatia K., Magrath I. and Kohn K. W. (1993) Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 53: 4776-4780
90. 90 Liu T. J., Zhang W. W., Taylor D. L., Roth J. A., Goepfert H. and Clayman G. L. (1994) Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54: 3662-3667
91. 91 Roth J. A., Nguyen D., Lawrence D. D., Kemp B. L., Carrasco C. H., Ferson D. Z. et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2: 985-991
92. 92 Sengelov L., Horn T. and Steven K. (1997) p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J. Cancer Res. Clin. Oncol. 123: 565-570
93. 93 Cote R. J., Esrig D., Groshen S., Jones P. A. and Skinner D. G. (1997) p53 and treatment of bladder cancer. Nature 385: 123-125
94. 94 Ribeiro J. C., Barnetson A. R., Fisher R. J., Mameghan H. and Russell P. J. (1997) Relationship between radiation response and p53 status in humun bladder cancer cells. Int. J. Radiat. Biol. 72: 11-20
95. 95 Hanzal E., Gitsch G., Kohlberger P., Dadak C., Miechowiecka N. and Breitenecker G. (1992) Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. Anticancer Res. 12: 2325-2329
96. 96 Ostrowski J. L., Sawan A., Henry L., Wright C., Henry J. A., Hennessy C. et al. (1991) p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J. Pathol. 164: 75-81
97. 97 Jost C. A., Murin M. C. and Kaelin W. J. (1997) p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-194
98. 98 Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819
99. 99 Bian J. and Sun Y. (1997) p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc. Natl. Acad. Sci. USA 94: 14753-14758
100. 100 Davidoff A. M., Humphrey P. A., Iglehart J. D. and Marks J. R. (1991) Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. USA 88: 5006-5010
101. 101 Casey G., Lopez M. E., Ramos J. C., Plummer S. J., Arboleda M. J., Shaughnessy M. et al. (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971-1981
102. 102 Jacquemier J., Moles J. P., Penault-Llorca F., Adelaide J., Torrente M., Viens P. et al. (1994) p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br. J. Cancer 69: 846-852
103. 103 Barnes D. M., Hanby A. M., Gillett C. E., Mohammed S., Hodgson S., Bobrow L. G. et al. (1992) Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340: 259-263
104. 104 Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L. et al. (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88: 173-182
105. 105 Flaman J. M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P. et al. (1995) A simple p53 functional assay for screening cell lines, blood and tumors. Proc. Natl. Acad. Sci. USA 92: 3963-3967
106. 106 Greenblatt M. S., Bennett W. P., Hollstein M. and Harris C. C. (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878
107. 107 Fearon E. R. and Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
108. 108 Lotem J. and Sachs L. (1993) Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82: 1092-1096
109. 109 Taubert H., Meye A. and Wurl P. (1996) Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 56: 4134-4136
110. 110 Vega F. J., Iniesta P., Caldes T., Sanchez A., Lopez J. A., de Juan C. et al. (1997) p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br. J. Cancer 76: 44-51
111. 111 Preudhomme C., Dervite I., Wattel E., Vanrumbeke M., Flactif M., Lai J. L. et al. (1995) Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J. Clin. Oncol. 13: 812-820
112. 112 Leach F. S., Tokino T., Meltzer P., Burrell M., Oliner J. D., Smith S. et al. (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53: 2231-2234
113. 113 Bueso R. C., Manshouri T., Haidar M. A., Yang Y., McCown P., Ordonez N. et al. (1996) Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37: 179-188
114. 114 Barbareschi M., Girlando S., Fellin G., Graffer U., Luciani L. and Dalla P. P. (1995) Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol. Res. 22: 349-352
115. 115 Ehrmann J. J., Kolar Z., Vojtesek B., Kala M., Komenda S. and Oulton A. (1997) Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299-304
116. 116 Jiang M., Shao Z. M., Wu J., Lu J. S., Yu L. M., Yuan J. D. et al. (1997) p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer 74: 529-534
117. 117 Gorgoulis V. G., Rassidakis G. Z., Karameris A. M., Papastamatiou H., Trigidou R., Veslemes M. et al. (1996) Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma. Mod. Pathol. 9: 544-554
118. 118 Zhou M., Yeager A. M., Smith S. D. and Findley H. W. (1995) Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85: 1608-1614
119. 119 Howley P. M. (1991) Role of the human papillomaviruses in human cancer. Cancer Res. 51: 5019s-5022s
120. 120 Garkavtsev I., Grigorian I. A., Ossovskaya V. S., Chernov M. V., Chumakov P. M. and Gudkov A. V. (1998) The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391: 295-298
121. 121 Kamijo T., Zindy F., Roussel M. F., Quelle D. E., Downing J. R., Ashmun R. A. et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659
122. 122 Sherr C. (1998) Tumor surveillance via the ARG-p53 pathway. Genes Dev. 12: 2984-2991
123. 123 de Stanchina E., McCurrach M. E., Zindy F., Shieh S. Y., Ferbeyre G., Samuelson A. V. et al. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434-2442
124. 124 Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J. C. et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969
125. 125 Yamamoto H., Sawai H., Weber T. K., Rodriguez B. M. and Perucho M. (1998) Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res. 58: 997-1003
126. 126 McCurrach M. E., Connor T. M., Knudson C. M., Korsmeyer S. J. and Lowe S. W. (1997) bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 94: 2345-2349
127. 127 Mao L., Hruban R. H., Boyle J. O., Tockman M. and Sidransky D. (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54: 1634-1637
128. 128 Sidransky D., Von Eschenbach A., Tsai Y. C., Jones P., Summerhayes I., Marshall F. et al. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709
129. 129 Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A. and Bunting P. S. (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer 58: 480-487
130. 130 Lubin R., Zalcman G., Bouchet L., Tredanel J., Legros Y., Cazals D. et al. (1995) Serum p53 antibodies as early markers of lung cancer. Nature Med. 1: 701-702
131. 131 Shaw P., Bovey R., Tardy S., Sahli R., Sordat B. and Costa J. (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA 89: 4495-4499
132. 132 Fujiwara T., Cai D. W., Georges R. N., Mukhopadhyay T., Grimm E. A. and Roth J. A. (1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86: 1458-1462
133. 133 Hupp T. R. and Lane D. P. (1994) Allosteric activation of latent p53 tetramers. Curr. Biol. 4: 865-875
134. 134 Selivanova G., Iotsova V., Okan I., Fritsche M., Strom M., Groner B. et al. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med. 3: 632-638
135. 135 O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M. et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300
136. 136 Wang Q., Fan S., Eastman A., Worland P. J., Sausville E. A. and O'Connor P. M. (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88: 956-965
137. 137 Gabrilovich D. I., Cunningham H. T. and Carbone D. P. (1996) IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J. Immunother. Emphasis Tumor Immunol. 19: 414-418
138. 138 Mayordomo J. I., Loftus D. J., Sakamoto H., De Cesare C. M., Appasamy P. M., Lotze M. T. et al. (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183: 1357-1365
139. 139 Lowe S. W. (1997) Progress of the smart bomb cancer virus. Nature Med. 3: 606-608
140. 140 Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D. D. and Kirn D. H. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3: 639-645